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Abstract
Background: Uncomplicated lower urinary tract infections (LUTI) are very common, and presumably around
200,000 female patients are treated for this annually in Denmark. The current Danish national clinical practice
guidelines recommend pivmecillinam as a first-line drug (i.e., 400 mg t.i.d. for 3 days). Pivmecillinam is also one of
the first-line drugs recommended in the international guidelines for LUTIs (i.e., 400 mg b.i.d. for 5 days). The
international recommended duration is based on evidence saying that a 7-day regimen is better than a 3-day
regimen. However, no data says that a 5-day regimen is superior to a 3-day regimen. With this study we aim to
identify and to compare the efficacy of pivmecillinam 400 mg t.i.d in a 3-day respectively 5-day regimen, against
community acquired uncomplicated LUTI, i.e., in women at the age of 18–70 year old.
Method/design: The general practitioner will at consultation give a suitable patient the opportunity to participate
in the study. If the patient will give her consent, a double-blinded kit (i.e., the antibiotic with/without placebo,
questionnaires and self-urinary samples) will be given to the patient. We aim for 161 evaluable patients in each arm.
Discussion: Pivmecillinam is an excellent choice against urinary tract infections and we believe this study will fill in
the gaps and strengthen the evidence on the treatment against one of the most common infections in our society.
Thus, aiming to provide a more rational and ecological beneficial antimicrobial therapy.
Trial registration: EudraCTno.: 2014-001321-32.
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Background
Uncomplicated lower urinary tract infections (LUTIs)
are very common (i.e. 10% of all women has it each year
and 60% of all women experience at least one episode
during their lifetime) [1], and we presume there are
about 200,000 patients treated for this in Denmark
annually. Most patients are otherwise healthy women,
and these infections are often the main reason of expos-
ure to antibiotics for these patients [2]. Uncomplicated
LUTIs are primarily community acquired and diagnosed
as well as treated in primary care. The most common
pathogen is Escherichia coli [2, 3], and diagnosis can be
made clinical with 90% positive predictive value (i.e. new
onset dysuria, pollakisuria and urgency, together with
absence of vaginal discharge or pain) [4].
In Denmark, the current clinical practice recommen-
dations is pivmecillinam (i.e., 400 mg t.i.d for 3 days) as
the first line drug against uncomplicated LUTIs [5].
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Pivmecillinam is a prodrug of mecillinam. It is an amidi-
nopenicillin, selective and highly effective against Gram-
negative bacteria, especially E. coli. The side effects are
few; most commonly reported are mild gastrointestinal
symptoms (e.g. nausea) [6]. It has for a long time pri-
marily been used for UTIs in the Scandinavian countries
[7]. Several studies have shown pivmecillinam to be a
safe and effective agent in the treatment of LUTIs [6, 8].
Even in countries where it is well used, there seems to
be low rates of resistance [3, 8, 9] (e.g. 5% resistance in
E. coli of the Danish primary sector [10]), and indica-
tions of a low rate of collateral damage and low risk of
clonal spread of resistance [11].
The current international and European clinical prac-
tice guidelines for acute uncomplicated UTI recommend
pivmecillinam as one of the first line drugs, the therapy
is recommended to be 400 mg b.i.d for 5 days. Although,
at the same time saying 400 mg b.i.d in any duration be-
tween 3 and 7 days is an appropriate choice, but point-
ing out a 5-day or a 7-day course probably is superior to
a 3-day course [2]. The recommended duration is, how-
ever, based on evidence showing a 7-day course is better
than a 3-day course [12]. Clinical studies on pivmecilli-
nam treatment of LUTI caused by ESBL producing bac-
teria shows different success rates, i.e. 56% (200 mg
t.i.d.) and 80% (mainly 400 mg t.i.d) [13, 14]. The higher
success rate of 400 mg is supported by Monte Carlo
simulations [15]. Thus, evidence point to a superiority of
400 mg dose.
With this knowledge, we wanted to compare the effi-
cacy of a 400 mg t.i.d. 3-day versus 5-day regimen of piv-
mecillinam against uncomplicated LUTI.
Methods
Design
This study will be a prospectively, double-blinded, ran-
domized, multi-center placebo-control trial, comparing
the efficacy of a 3- and 5-day regimen of pivmecillinam
400 mg. t.i.d. against uncomplicated urinary tract infec-
tions. The study will be conducted according to good
clinical practice (GCP) and each patient has to sign a
consent form to be able to participate.
Study population
Inclusion criteria
Women in the age of 18–70 years old, with clinical fea-
tures of community acquired uncomplicated LUTI, with
the ability to understand the study and give consent, can
participate. Patients need to have a symptom cumulative
score of ≥2 p (i.e. none, mild, moderate or severe, scor-
ing 0–3, respectively) in accordance to the validated
questionnaires for uncomplicated UTI [16]. The follow-
ing symptoms are included:
 Dysuria (i.e. pain or burning sensation when urinating)
 Urgency (i.e. feeling an increased and more frequent
need to urinate)
 Pollakisuria/frequency (i.e. urinating more frequently
than usually)
An accepted definition of uncomplicated LUTI is symp-
toms in concordance with uncomplicated LUTI and sig-
nificant bacteriuria of uropathogenic bacteria [1], but we
choose not to include the latter criteria in our intention to
treat (ITT) analysis. This is because we want the included
patients in the ITT group to mimic the realistic settings as
much as possible (i.e. in which patients with uncompli-
cated LUTI will receive antibiotic therapy without urine
samples in most primary care settings).
Key exclusion criteria
 Allergy to penicillins and cephalosporines.
 Clear signs of (i.e. high fever ≥38,5 °C or flank pain/
tenderness) or high suspicion of pyelonephritis.
 Any condition that may lead or predispose to
complicated urinary infection (i.e. indwelling urinary
catheter, pregnancy, immunosuppressive therapy,
abnormal urinary tracts, recurrent UTI, serious
neurological disease affecting the bladder).
 Porphyria or systemic primary carnitine deficiency
or of the type organic aciduria (i.e. methylmalonic
aciduria and propionacid anemia).
 Symptoms correlating with differential diagnosis (i.e.
vaginal discharge or pain).
 Ongoing/current antibiotic therapy.
 Oesophageal stricture.
 Current intake of allopurinol (i.e. increases the risk
of allergic skin reaction to mecillinam) or
probenecid (i.e. decrease the renal excretion of
mecillinam) or valproate.
 Currently part of another clinical trial. Inability/unable
to understand and/or take part in the clinical trial
Settings and recruitment
The patients will be recruited in general practice (GP)
clinics by GPs in Denmark. With nine collaborating
clinics we aim to recruit 161 evaluable patients in each
arm over app. 24 months. Female patients will, during
this period, be screened for uncomplicated LUTI and re-
cruited to the study. To receive the treatment goal as
soon as possible the investigators will contact and sup-
port the GPs from time to time during the trial period.
Intervention
All patients included will receive pivmecillinam therapy
for 3 days or 5 days. The 3-day regimen group will
receive blinded placebo tablets on day 4 and 5. If a
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secondary antibiotic treatment is required due to
treatment failure (i.e. ongoing or worsening symptoms),
a new antibiotic cure will be chosen in line with the
results from the pre-treatment (inclusion day) urine
culture. The GPs will be at any time welcome to call the
Department of Clinical Microbiology (DCM) (i.e. central
investigation site) for consultation in the matter.
Drug processes and randomization All drug process
will be conducted according to the requirements of
Good Manufacturing Practice (GMP) and Good Distri-
bution Practice (GDP), in accordance with the Danish
Health and Medicine Authority. The placebo tablets will
be indistinguishable from the pivmecillinam tablets (i.e.
in color, taste and design), and packaged in an identical
blister-packaged (i.e. the commercial pivmecillinam
blister-package). To guarantee blinding of both the pa-
tients, treating physicians and the investigators, a central
randomization will be conducted by an independent
qualified researcher. The randomization will be con-
ducted in R 3.2.2 [17], with each kit given a number
from 1 to 500 and randomized into 25 blocks including
20 kits each. The kits will be delivered to the collaborat-
ing clinics. Encrypted data will be stored centrally at the
hospital research department and the collaborating
hospital pharmacy for possible de-blinding.
Questionnaires
The GP will receive an inclusion-questionnaire that he/
she will fill out on day 0 (inclusion day). The question-
naires his will include age, positive inclusion criteria (i.e.
LUTI symptom load), exclusion criteria, debut date of
symptoms, and annual incidence of LUTI. All partici-
pants will be given a diary-questionnaire for day 0 to day
7. In which they daily will answer questions on LUTI
symptoms, score them of severity on daily bases and re-
port on which day they feel completely cured (i.e. back
to habitual conditions). They will also be asked to
register impairment in daily life activities and quality (i.e.
work, physical activity, sleep, mental well-being) similar
to the symptom score, previous UTI, travel, weight (i.e.
>70 kg) possible adverse effects, adherence to the ther-
apy, use of analgesics and other optional information.
The patient will also receive a second follow-up
questionnaire which need to be filled out once anytime
around day-28 (i.e. possible symptoms or side effects
since end of therapy, current status of questions asked
in the symptom-diary). All questionnaires on symptoms
are constructed according to the validated question-
naires for LUTI symptom score [16]. They will be
submitted together with the urine samples. All of the
patients’ questionnaires will be so patients can easily
understand and answer the questions.
Microbiological diagnostics
One pre-treatment urine sample (day 0) with optional
urine-dipstick, and two control urine samples (day 8–10
and day 28–30, respectively) will be sampled from the
patient. The three urine samples will be sent to the
DCM, Hvidovre University Hospital, Denmark, for
examination of the presence and count of uropathogenic
bacteria. In presence of significant bacteriuria (i.e. ≥103
bacteria/ml [E. coli] / ≥104 bacteria/ml [other uropatho-
genic bacteria]) the isolates will also be examined for re-
sistance mechanisms and patterns, minimal inhibitory
concentration (MIC) to mecillinam (i.e. by E test, AB
Biodisk, bioMe’rieux, Marcy-l’E’ toile, France) and
determining the bacterial specimen (i.e. MALDI-TOF,
Brukner, Germany). All urine samples will processed
according to laboratory routine and susceptibility tested
according to EUCAST guidelines [18]. During the study
all significant uropathogenic isolates will be stored at
minus 80 °C. At the end of the study these isolates will
be genetically examined to determine their more specific
identity/type, i.e. so we can evaluate if the potential re-
lapse is either a true relapse or a reinfection (i.e. the
same or different type of bacterial specimen).
Data collection and procedures
Standardization
To the most possible standardized and similar inclusion
process all GPs participating in the study will be
educated in the inclusion procedures by the principal
investigator and one senior investigator whom will visit
all clinics before the initiation of the study.
Day 0/inclusion
When consulting a patient examined and considered a
suitable participant according to the inclusion and exclu-
sion criteria, the GP will give the patient the opportunity
to participate in the study. If the patient is still willing to
participate, the patient will sign a form of consent with
the GP, be scored by the GP on initial symptom load,
and give a urine sample which will be sent with the
questionnaire to the central laboratory and optionally
examined with dipstick
Follow-up
The investigators at the central laboratory will be calling
or sending text messages (patient’s decision) to the in-
cluded patients to follow-up on the questionnaires and
control urine-samples, as well as answering any ques-
tions the patients might have. The phone calls or text-
messages are app. made on day 3–5, day 9–11 and day
28–30, respectively. However, not at any time will we try
to increase the adherence to the treatment, since the
study ought to be mirroring a realistic patient situation.
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Criteria for termination from the study
If a patient during the study would develop signs of upper
UTI (i.e. pyelonephritis), treatment failure, serious adverse
effects or allergic reactions to the medicine, or decision of
withdrawal, she will have to terminate from the study and
possibly get a new evaluation by a physician.
Second medical consultation
Patients will be told at recruitment to visit the GP again
if she develops worsening of symptoms or not experien-
cing any symptom relief during the study period. In that
case the GP is able to choose a new treatment strategy
for the patient and will have the potential microbio-
logical diagnostic answers (i.e. from pre-treatment urine
sample) to take in consideration in this approach.
Outcome
Primary endpoint
We have two co-primary endpoints:
 Co-primary endpoint no. 1 –clinical efficacy (i.e.
which group will be clinically cured fastest and
proportion of patients cured at day four).
 Co-primary endpoint no. 2 – bacteriological efficacy
(i.e. proportion of patients bacteriologically cured at
first control urine sample).
Secondary endpoints
 Clinical signs and symptoms in uncomplicated
LUTIs in women.
 Frequency and timing of relapse of symptoms and/
or bacteriuria.
 Bacteriological findings (i.e. ESBL producing bacteria).
 Complications (i.e. urosepsis and/or pyelonephritis)
within 28 days.
Definitions
 Clinically cured is defined as cumulative symptom
score of <2.
 Clinical relapse is defined as initial clinically cured
followed by cumulative clinical score of ≥2 at day 28.
 Bacteriologically cured is defined as significant
reduction (i.e. ≥ 102 fold decrease in uropathogenic
bacteria) or potentially full eradication of
uropathogenic bacteria (i.e. sterile culture or
asymptomatic contaminations of non-uropathogenic
bacteria).
 Bacteriological relapse is defined as initially
bacteriologically cured followed by significant
growth at day-28, with the same bacteria. Growth of
other uropathogenic bacteria is defined as
reinfection.
Procedures to evaluate endpoints
By comparing the questionnaires we can evaluate the
clinical endpoints. By examining the urine samples we
can evaluate the bacteriological endpoints. By asking
for a questionnaire on day 28 we can evaluate any
relapse/reinfection, hospitalization or secondary con-
sultation, and afterwards look in the collaborating
department of clinical microbiology’s databases for
urosepsis or pyelonephritis.
Power, sample size and analysis
Definitions
The intention-to-treat (ITT) analysis will be consisting
of all included patients (i.e. patients that present with
symptoms of uncomplicated LUTI and are included in
the study). The per-protocol (PP) analysis will be con-
sisting of all the patients that follow-up with clinical and
bacteriological data (i.e. excluding the dropouts). The
need-to-treat (NTT) analysis will be stratified from the
PP analysis to only include patient with true uncompli-
cated LUTI (i.e. symptoms and significant bacteriuria,
only isolates susceptible to mecillinam).
Power analyze
We hypothesize that there is a 15% absolute differences
in efficacy between the groups, measured in clinical ef-
ficacy. We believe there to be an even bigger difference
in bacteriological efficacy. Assuming an efficacy of 90
and 75% for 5 days and 3 days therapy, respectively,
using a double-sided test with p < 0.05, and a statistical
power of 0.8, we will need 113 patients in each group
for the NTT analysis. With an estimated fall-out rate of
app. 30% between each arm; 161 patients per group will
need to be included for the PP analysis, and 230 in each
group for the ITT analysis. There is a possibility for an
interim analysis after 300 included participants, since
we cannot reject a possibility for a higher (i.e. 20%)
absolute efficacy.
Data processing and statistical analysis
The source data is the GP’s and patient’s questionnaires
and the diagnostics answers from the microbiological lab
at the DCM. All source data will all be stored by the in-
vestigator and sponsor, in originals and scanned copies,
at the DCM. The collected source data are transferred,
logged and processed in the computers of the DCM.
Analysis will be made in ITT, PP, and NTT form, re-
spectively. All data will be analyzed coded, and only de-
coded after the analysis is done and the analytic results
are written in the relevant sections in the future article.
The statistical software packages SAS (SAS Institute,
Cary, NC) will be used for all analyses. Categorical data
will be analyzed using a Fisher’s Exact test.
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Presentation of the results
Results (i.e. positive, negative and/or inconclusive) will be
presented at scientific meetings, and in scientific publica-
tions in accordance to CONSORT 2010 statement [19].
Ethical considerations
The study will comply with all the requirements to se-
cure patients safety and to be carried out according to
the Declaration of Helsinki, national laws and regula-
tions. Ethical approval has been obtained by the Danish
committee on biomedical research ethics for the capitol
region of Denmark (No. H-4-2014-072). Approvals have
also been obtained from the Danish National Health and
Medicines Authority and the Danish Data Protection
Agency. The study will be conducted according to the
principle of Good Clinical Practice (GCP) and moni-
tored by the GCP Unit of Bispebjerg Copenhagen Uni-
versity Hospital, Denmark. All patients will be included
in concordance with rights of a research subject in clin-
ical research, according to the national committee of
health and research ethics document, which each subject
will be provided the option to read before deciding to
participate. The informed consent is obtained at the GP
office, where the participant also will be informed about
potential risks, benefits and procedures etc. based on an
information sheet that the central investigators have pre-
pared in concordance with above mentioned commit-
tees’ standards. The patient can withdraw their consent
at any time without disadvantages.
Data storage
The study will comply with the Danish regulation about
management of personal information by the act on pro-
cessing of personal data (Act No. 429 of 31 May 2000).
All patient data will be carefully processed and stored at
the Department of Clinical Microbiology, Hvidovre Uni-
versity Hospital, Denmark. All data will be anonymous
in any possible future publication.
In trial intervention
The only time during the study in which we will intervene
with antimicrobial therapy is if we during microbiological
diagnostics find out that the patient is receiving a possibly
ineffective therapy. This will for example be the case if we
find causing uropathogenic bacteria to be:
1. resistant to mecillinam (i.e. a small proportion of
uropathogenic bacteria) [9]
and/or
2. a specimen to which pivmecillinam is not
recommended for various reasons (non-susceptible,
natural resistance etc.) - i.e. Pseudomonas spp.,
Acinetobacter spp., or Enterococcus spp. and other
Gram positive uropathogenic bacteria etc.
We will then make contact and recommend another
more suitable antimicrobial therapy.
Adverse effects/risks
Pivmecillinam has been proven in RCTs to be safe and ef-
fective in the treatment of UTIs [6, 8, 20]. The risk off
selecting and spreading off for mecillinam resistant bacteria
is at very low risk [11], and mecillinam has a minor impact
on the normal microflora [21]. Side effects are not more
common than in any other penicillin, severe side effects are
very rare, and the most common side effects are gastro-
intestinal complaints (i.e. nausea). Other common side-
effects are rash and vulvovaginitis [6]. In the questionnaires
the patients will be asked for possible adverse effects on
day 1–7 and day 28. Any adverse reactions, serious adverse
reactions or events during the study period will be reported
according to GCP principles and in concordance with the
Danish National Health and Medicine Authority.
Discussion
Pivmecillinam is an excellent choice against urinary tract
infections, and has shown to be both safe and effective
against UTI [6, 12, 22], with a clear superiority to placebo
[12] and superiority to sulftamethiazole [22]. In these days,
with the concerning rise of multidrug-resistant bacteria,
pivmecillinam has shown to be of an especial advantage;
demonstrating low collateral damage (i.e. minor impact
on the normal microflora [21], low resistance [3, 9], low
selectivity and clonal spread of resistance [11]), as well as
indication of clinical and bacteriological effective against
ESBL producing Enterobacteriaceae [13, 23]. Hence, there
are good evidences backing pivmecillinam as a first line of
drug in the treatment of LUTI, as stated in the inter-
national guidelines [2], and as long time practiced in the
Scandinavian countries.
Ferry et al. [12] have demonstrated that a 7-day regimen
is superior to a 3-day regimen against uncomplicated
LUTI. However, the current guidelines do not recommend
a 7-day therapy, because of the increased risk of side ef-
fects (i.e. GI-problems). Nevertheless, there are no data
comparing the 3-day vs. the 5-day therapy. With the 5-day
therapy possibly to be more effective and with non-
significant increased risk of side effects than the 3-day; a
5-day therapy might be a more cost-beneficial duration
for the patient in the treatment of uncomplicated LUTI.
Thus, with this study we want to strengthen and fill the
gaps of evidence in our guidelines.
We have chosen the 400 mg dose t.i.d., since that is the
dose we recommend in Denmark; and we believe 200 mg
t.i.d to be an insufficient dose (i.e. supported by pharma-
cokinetic mouse models [15] and the recent study from
Soraas et al. [14]). With this knowledge, we believe it to be
unethical of us to use a 200 mg dose, and have therefore
excluded a treatment arm with 200 mg.
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Design and definitions
We designed this protocol similarly to previous similar clin-
ical studies on uncomplicated LUTI [12, 22, 24, 25], in
order to be able to compare results in the future in a more
accurate way. We define uncomplicated LUTI in concord-
ance with the acknowledged definition [1, 26], with one
difference; we choose to include post-menopausal women
in our study, since we do not necessarily believe them to al-
ways be of complicated LUTI. Hence, if a post-menopausal
woman has no other complicated conditions (see exclusion
criteria) we believe her to be a potential candidate.
Procedures
We want the inclusion procedures to be as realistic as
possible. Therefore, the consulting with the GPs will be
changed as little as possible and restricted to the inclu-
sion day. However, patients will be clearly instructed to
return to the GP as usual at sign of treatment failure, or
if they wish to consult for any other reason.
Outcomes
The primary outcome we want to focus on is the clinical
effect, since that is of most importance to the patient.
However, it is important to know that the bacteria dis-
appear and not cause clinical relapses in the future;
therefore, we included two follow-up urine sample at
day-4 and day-28, respectively.
Scientific and societal perspective
This study will give us the knowledge of what drug ther-
apy of pivmecillinam that is most effective and sufficient.
If the 5-day therapy will show to be significantly superior
to the 3-day regimen, the current guidelines will have to
be changed in best interests of the patients. Also through
the perspective of the patients, it will be beneficial if the 3-
day regimen is proven to be non-inferior to the 5-day regi-
men (i.e. higher rate of compliance, and less antimicrobial
consumption cause less economic and ecological loads),
and we can keep using the 3-day regimen in concordance
with the principles of evidence-based medicine.
Conclusion
We believe this study will fill the scientific gaps and pro-
vide sufficient evidence for the most efficient dose dur-
ation of pivmecillinam against uncomplicated lower
urinary tract infections. Thus, strengthening the guide-
lines for one of the most common community acquired
infections in our society.
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